共 50 条
- [41] Impact of SGLT2 inhibitors on cardiovascular outcomes and metabolic events in Chinese han patients with chronic heart failureDIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):Li, FeiBaheti, RewaanJin, MengyingXiong, WeiDuan, JiaweiFang, PengWan, Jing
- [42] The Risk of Cardiovascular (CV) Events After Initiation of SGLT2i, GLP-1RA, DPP4i, or SUs in Patients With T2D and Low-to-Moderate CV RiskPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 86 - 87Tesfaye, HelenPaik, Julie M.Alix, CarolineDiCesare, Elyse C.Cromer, Sara J.Everett, Brendan M.Glynn, Robert J.Wexler, Deborah J.Patorno, Elisabetta
- [43] Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 1 diabetesDIABETES-METABOLISM RESEARCH AND REVIEWS, 2020, 36 (02)Zhou, YueGeng, ZhuangWang, XiangHuang, YajingShen, LiyanWang, Yangang
- [44] Protective Effect of GLP-1 Receptor Agonists (GLP-1 RA) and SGLT2 Inhibitors (SGLT2i) against Adverse Cardiovascular (CV) Events in HIV and Type 2 Diabetes Mellitus (T2DM) When Compared with Metformin Alone: A National Database StudyDIABETES, 2020, 69Alaber, Omar A.Chandar, Apoorva K.Dahash, Basma A.Zuzek, Aleona C.Rajpal, Aman
- [45] Cardiovascular risk and safety of SGLT2 inhibitors versus DPP-4 inhibitors: A nationwide comparative effectiveness research studyPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 145 - 145Yang, LantingGabriel, NicoGuo, Serena JingchuanEmpey, Kerry M.Suh, KanghoKane-Gill, Sandra L.Kirisci, LeventHernandez, Inmaculada
- [46] Taking position: Effect of SGLT2i on arterial pressure, vascular damage, kidney disease and associated cardiovascular riskREVISTA DE NEFROLOGIA DIALISIS Y TRASPLANTE, 2024, 44 (02): : 49 - 51Inserra, FelipeForte, EzequielElbert, AliciaWaisman, GabrielCastellaro, CarlosBuso, CarlosFairman, EnriqueCobo, Augusto LavalleManucha, WalterSalmeri, EmilianoSanabria, HugoSanchez, RamiroTerns, Paula PerezAranguren, FlorenciaArias, PabloCastano, YaninaDe Marziani, GuillermoFaingold, CristinaGonzalez, JoaquinJawerbaum, AliciaVazquez, FabianaWappner, DiegoZaidel, Ezequiel J.Aiello, Ernesto A.Alfie, JoseDe Cerchio, AlejandroChoi, MarceloMarquez, DiegoPiskorz, DanielPupi, Luis MariaRenna, NicolasSalazar, MartinDorado, EnriqueFerder, LeonLavenia, GustavoOrias, MarceloPaganti, Luciana GonzalezRigo, Diego H.Diez, Guillermo RosaSivak, LeonardoTrimarchi, HernanMajul, ClaudioSinay, IsaacMarin, MarcosBonanno, Carlos
- [47] USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN POPULATIONS WITH NASH OR AT RISK OF NASH IN US CLINICAL PRACTICEGASTROENTEROLOGY, 2020, 158 (06) : S1446 - S1446Lai, MichelleBroestl, JeremyJuneja, KavitaMilligan, ScottRadtchenko, JannaYounossi, Zobair M.Afdhal, Nezam H.
- [48] Cardiovascular Protection of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Type 2 Diabetes Mellitus; Literature ReviewINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES, 2021, 10 (02): : 139 - 143Alsaedi, Ziyad AliAlahmadi, Khalid MohammedKhan, Abdulaziz ZakariaAlrait, Ezzaddin MugahedAl Ghamdi, Mohammed KhaledAlqahtani, Abdullah MutrikAlkahmous, Hadil AliAlanazi, Rakan SalehAljohani, Anas AbdulrhmanAlsawyan, Wessam AhmedAlmazariqi, Faisal Ayedal Jabal, Abdullah Oudah Saeed
- [49] Use of GLP-1 receptor agonists (GLP1A) and/or SGLT-2 inhibitors (SGLT2I) in populations with NASH or at risk of NASH in US clinical practiceJOURNAL OF HEPATOLOGY, 2020, 73 : S452 - S452Lai, MichelleBroestl, JeremyJuneja, KavitaMilligan, ScottRadtchenko, JannaYounossi, ZobairAfdhal, Nezam
- [50] The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-AnalysisMETABOLITES, 2022, 12 (10)Xu, ChunmeiHe, LipingZhang, JingXu, LusiDong, JianjunLiao, Lin